Clinical trials: Juvenile Myositis Above the Age of 18

Polymyositis, Dermatomyositis

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

• Completed
• Age: 18 years and older
• Phase 3
• Injection or infusion
• Results posted

Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Conditions

Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis

Trial name

NCT02971683

Testing

Abatacept subcutaneous

Where

79 sites in United States, Australia and 9 more

Volunteers

149 people

Sponsor

Bristol-Myers Squibb